UNSPSC 51172337: Linaclotide

An oligo-peptide agonist of guanylate cyclase 2C. It was approved by the FDA in August 2012 and by the European Medicines Agency[4] for the treatment in adults of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

UNSPSC 51172337 Linaclotide, a Commodity code, encompasses pharmaceutical products procured by state and local jurisdictions for corrections, health services, and cooperative purchasing programs. Based on recent solicitations, state and local governments buy linaclotide and related prescription pharmaceuticals through formal procurement vehicles including direct contracts with manufacturers, cooperative purchasing alliances, and specialized health service agreements. The issuing bodies span county corrections departments, state health and human services commissions, and multi-state cooperative purchasing organizations serving corrections, public health, and employee benefit programs. The work solicited under this code includes specimen collection and drug testing services tied to pharmaceutical screening and confirmation protocols, direct-to-manufacturer prescription fulfillment programs for state pharmacy benefit initiatives, and generic and branded pharmaceutical products distributed through authorized wholesalers to state and local government facilities.

Activity concentrates in Texas and Minnesota, with recent solicitations reflecting both individual jurisdiction procurement and cooperative purchasing vehicles serving multiple states. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services, with a response deadline of July 23, 2026 and an estimated contract value of $600,000 for a two-year term commencing September 1, 2026; this procurement encompasses immunoassay screening, LC/MS/MS or GC/MS confirmation, and alternative testing methodologies supporting criminal justice supervision. The Texas Health and Human Services Commission issued Request for Information HHS0017013 (closed April 3, 2026) to evaluate vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to establish direct pharmaceutical supply relationships outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 with a response deadline of March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon through authorized wholesalers including Cencora, Cardinal Health, and Morris & Dickson.